FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today results from the independent Data Monitoring Committee (DMC) that is overseeing the Company’s ongoing U.S. pivotal trial evaluating Augment Bone Graft for the treatment of foot and ankle fusions. Based on the DMC’s review of all available safety data from the first 254 patients and a futility analysis on data from the first 79 patients to have completed their six month follow up visit, the DMC has recommended that the Company’s pivotal trial should proceed unchanged.
